Molina Healthcare, Inc.

Molina Healthcare, Inc. (MOH) Market Cap

Molina Healthcare, Inc. has a market capitalization of $10.21B.

Price: $195.62

0.92 (0.47%)

Market Cap: 10.21B

NYSE · time unavailable

CEO: Joseph Michael Zubretsky

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2003-07-02

Website: https://www.molinahealthcare.com

Molina Healthcare, Inc. (MOH) - Company Information

Market Cap: 10.21B|Sector: Healthcare

Company Profile

Molina Healthcare, Inc. offers comprehensive managed health care services, primarily targeting economically disadvantaged families and individuals. The company provides coverage through key government initiatives such as Medicaid and Medicare programs, in addition to state health insurance marketplaces. Its operations are strategically segmented into four main divisions: Medicaid, Medicare, Marketplace, and a general "Other" category. By the close of 2021, specifically December 31st, Molina Healthcare's network extended to approximately 5.2 million members across 18 states, all of whom qualified for Medicaid, Medicare, or other government-sponsored healthcare plans. Established in 1980, the company maintains its corporate headquarters in Long Beach, California.

Analyst Sentiment

53%
Hold

From 19 Active Polls

1Y Forecast: $194.46

▼ -0.6% Potential Upside

Consensus Target Metrics

Low Bound

$124

Median

$202

High Bound

$286

Average

$194

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$194.46
▼ -0.59% Upside
Low Target
$124.00
-37% Risk
Median Target
$202.00
3% Mid
High Target
$286.00
46% Max
Consensus
Buy
17 / 39 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)10,21111,7326,7988,81510,25716,17617,98516,70619,847
Enterprise Value ($M)9,17910,7005,4318,5179,88815,24016,89515,16217,644
Price to Earnings Ratio (P/E)1222.6248.05123.43-15.4431.6815.6515.0516.6515.22
Price/Earnings-to-Growth Ratio (PEG)66.5072.416.232.4410.833.27
Price to Sales Ratio (P/S)0.231.080.630.770.891.421.611.591.92
Price to Book Ratio (P/B)2.412.811.672.172.453.514.173.724.16
Price to Free Cash Flow Ratio (P/FCF)37.68-36.216.44-29.68-62.93-47.02107.05-71.0923.68
Enterprise Value to Sales (EV/Sales)0.980.500.750.861.331.521.441.71
Enterprise Value to EBITDA (EV/EBITDA)24.7457.8444.52-72.1854.3335.3635.1235.4334.33
Debt to Equity Ratio-2.780.950.970.970.920.770.870.690.53

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MOLINA HEALTHCARE INC (MOH) — Investment Overview

🧩 Business Model Overview

Molina Healthcare is a managed care organization (MCO) that contracts with government payors (primarily Medicaid, and also Medicare-related programs in certain geographies) to administer health benefits for enrolled members. The economic engine is straightforward: Molina receives per-member-per-month (PMPM) revenue based on eligibility and risk-adjustment mechanics, then finances clinical care through a mix of provider payments (capitated, fee-for-service, and value-based arrangements).

The value chain is anchored in (1) state contracting and bid processes, (2) actuarial modeling and risk scoring to price benefits accurately, (3) care delivery operations (utilization management, member engagement, and provider network management), and (4) regulatory and quality reporting that affects payment levels. In MCOs, membership growth and retention depend heavily on contract renewals and performance scoring, which directly links operations to cash flow.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly recurring in nature through PMPM payments, with contractual risk adjustment and quality-linked components that can raise or lower revenue relative to benefit cost. Key monetisation drivers include:

  • PMPM Medicaid/Medicare-related premiums: Core recurring revenue stream; sensitivity to risk coding, eligibility mix, and state-specific benefit structures.
  • Risk adjustment and quality incentives: Payments tied to diagnoses coding, HEDIS measures, and program requirements can materially influence margin stability.
  • Provider cost management: Operating margin depends on whether Molina’s pricing and care management reduce avoidable utilization without impairing quality metrics.

Margin drivers are less about absolute premium growth and more about the discipline of underwriting and the ability to translate clinical operations into lower medical cost trend, while maintaining compliance and quality performance required for sustained contract participation.

🧠 Competitive Advantages & Market Positioning

Molina’s moat is best described as a combination of regulatory barrier and operational switching friction created by contracting, reporting requirements, and network build-out. While enrollment can be mobile, state contracting and performance measurement make provider and member-care ecosystems difficult to replicate quickly.

  • High Barriers to Entry (FDA-equivalent in practice: contracting/quality compliance): Government programs require bid approvals, solvency/financial standards, detailed reporting, and strict compliance. Non-compliance can jeopardize eligibility, making “entry by marketing” ineffective.
  • Quality reporting and risk adjustment know-how: Accurate coding and performance measurement are operational capabilities. Competitors must execute similarly to compete on both price and quality.
  • Integrated care operations for complex populations: Molina’s model is designed for higher-acuity, lower-income and dual-eligible member sets where care management, network enablement, and utilization management materially affect medical loss ratio.

Competitive benchmarking:

  • Centene (CNC): Broad Medicaid exposure and also relies on state contracting depth; both compete on underwriting accuracy and compliance for government programs. Molina’s focus aligns more tightly with targeted Medicaid/Medicare-related geographies and product fit.
  • UnitedHealth Group (UNH) — Optum/UnitedHealthcare: More diversified across commercial and Medicare Advantage. United’s breadth can support cross-subsidisation, while Molina’s concentration can provide sharper operational focus on government programs.
  • Humana (HUM): More Medicare Advantage weighted. Humana competes in a different benefit and risk environment, with Medicare program dynamics and provider arrangements that differ from Medicaid-centric models.

Relative positioning: Molina’s competitive advantage is tied to executing in Medicaid and related government programs where contracting, compliance, and care-management performance are determinative—and where scaling successfully requires proven operational infrastructure rather than brand-driven demand.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth and earnings power in health insurance depend on the interplay between population demographics, program design, and the ability to manage medical cost trend. Key structural drivers include:

  • Program enrollment and demographic tailwinds: Aging demographics and persistent demand for public insurance coverage support steady membership baselines in government-sponsored programs.
  • Value-based care adoption: Incentives and reimbursement models increasingly reward quality outcomes and cost management; MCOs with execution capability can convert care delivery into more stable margins.
  • State contracting cycles and geographic expansion: Successful bidding and renewals can expand footprint. Contract awards reward demonstrated performance, compliance, and actuarial credibility.
  • Risk adjustment sophistication: As diagnosis coding, risk stratification, and program compliance evolve, operational maturity can protect pricing accuracy and margin quality.

⚠ Risk Factors to Monitor

  • Regulatory and contracting risk: Changes in Medicaid/Medicare program rules, reimbursement methodology, eligibility definitions, and quality requirements can alter PMPM economics and required compliance costs.
  • Medical cost trend and utilization shocks: Price and utilization dynamics can diverge from actuarial assumptions, pressuring margin and cash generation.
  • Provider network and reimbursement pressure: Network performance, provider contracting terms, and referral/authorization workflows influence medical costs and quality metrics.
  • Risk adjustment and coding scrutiny: Payment depends on risk scoring and documentation. Errors or compliance failures can lead to revenue pressure and reputational/regulatory consequences.
  • Operational complexity: Scaling across states requires robust systems for claims, quality reporting, care management, and compliance—execution missteps can be costly.

📊 Valuation & Market View

The market typically values managed care insurers using a blend of earnings multiples (commonly EV/EBITDA or P/E depending on analyst preference) and quality-of-earnings frameworks that focus on durability of medical margin and the sustainability of membership and contract performance. Drivers that move valuation expectations include:

  • Medical loss ratio trajectory: Stability versus volatility in medical cost trend.
  • Quality scores and compliance: Ability to sustain incentives and avoid payment reductions.
  • Risk adjustment credibility: Consistency in coding practices and reduced likelihood of payment clawbacks or restatements.
  • Capital and reserve discipline: Insurers with resilient reserve and solvency practices tend to command a higher confidence premium.

Because revenues are contractually recurring but margins can swing with medical and regulatory factors, valuation tends to be more sensitive to earnings quality and execution than to simple topline growth.

🔍 Investment Takeaway

Molina Healthcare’s long-term investment case rests on a defensible position in government-sponsored managed care, supported by regulatory and operational barriers to entry, and the practical switching friction created by state contracting, compliance, and quality/risk-adjustment capabilities. The core question for sustained outperformance is the company’s ability to keep underwriting accuracy and care-management execution aligned with evolving reimbursement and medical cost dynamics while maintaining quality performance that protects PMPM economics.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MOH.

zacks.com2026-07-24

Are Investors Undervaluing Molina Healthcare (MOH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

seekingalpha.com2026-07-23

Molina Healthcare, Inc. (MOH) Q2 2026 Earnings Call Transcript

Molina Healthcare, Inc. (MOH) Q2 2026 Earnings Call Transcript

gurufocus.com2026-07-23

Is Molina Healthcare Inc (MOH) a Bargain After 9.7% Drop? GF Value Says Undervalued

On July 23, 2026, Molina Healthcare Inc (MOH) shares fell 9.7%, closing at $200.29. This decline comes amid a broader context of price fluctuations, with the st

zacks.com2026-07-23

MOH Q2 Earnings Beat on Lower Operating Expenses, 2026 EPS View Raised

Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.

zacks.com2026-07-22

Here's What Key Metrics Tell Us About Molina (MOH) Q2 Earnings

The headline numbers for Molina (MOH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com2026-07-22

Molina (MOH) Q2 Earnings Top Estimates

Molina (MOH) came out with quarterly earnings of $1.51 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $5.48 per share a year ago.

businesswire.com2026-07-22

Molina Healthcare Reports Second Quarter 2026 Financial Results

LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported second quarter 2026 GAAP income per diluted share of $1.19 and adjusted income per diluted share of $1.51. Financial results are summarized below:     Three months ended   Six months ended     June 30,   June 30,     2026   2025   2026   2025                   (In millions, except per-share results) Premium Revenue   $10,244   $10,868   $20,416   $21,496 Total Revenue   $10,874   $11,427   $2.

zacks.com2026-07-21

Exploring Analyst Estimates for Molina (MOH) Q2 Earnings, Beyond Revenue and EPS

Beyond analysts' top-and-bottom-line estimates for Molina (MOH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

prnewswire.com2026-07-16

Molina Healthcare Set to Join S&P MidCap 400 and Construction Partners to Join S&P SmallCap 600

NEW YORK, July 16, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent Molina Healthcare Inc. (NYSE: MOH) will replace National Storage Affiliates Trust (NYSE: NSA) in the S&P MidCap 400, and Construction Partners Inc. (NASD: ROAD) will replace Molina Healthcare in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 22. S&P 500 constituent Public Storage (NYSE: PSA) is acquiring National Storage Affiliates Trust in a deal that is expected to be completed on or about that date pending final conditions.

zacks.com2026-07-01

Is Molina Healthcare (MOH) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

fool.com2026-06-30

State Street SPDR Small Cap ETF Outpaces iShares on Returns

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offering unique advantages for investors.

zacks.com2026-06-29

Molina (MOH) Soars 6.3%: Is Further Upside Left in the Stock?

Molina (MOH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

247wallst.com2026-06-26

The Greenblatt Magic Formula: How H&R Block, Molina, and Peabody Stack Up for Retirement Investors

Joel Greenblatt's Magic Formula ranks stocks on two factors: earnings yield (EBIT divided by enterprise value) and return on capital.

247wallst.com2026-06-18

Michael Burry Called the 2008 Crash. Now He's Shorting Nvidia to Buy This Boring Healthcare Stock.

Before Michael Burry shut down Scion Asset Management in late 2025 and pivoted to publishing a Substack newsletter warning of an “AI Bubble,” his final 13F filings reportedly disclosed put options against NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) and Palantir (NASDAQ:PLTR) alongside a heavy rotation, around 51% of the disclosed portfolio, into health insurer Molina Healthcare.

businesswire.com2026-06-17

Molina Healthcare of Michigan and The MolinaCares Accord Donate $275,000 to Genesee County Habitat for Humanity

FLINT, Mich.--(BUSINESS WIRE)--Molina Healthcare of Michigan and The MolinaCares Accord donate $275,000 to Genesee County Habitat for Humanity.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"MOH (Q2’26, ended 2026-06-30) reported Revenue of $10.87B and Net Income of $60M, with EPS of $1.19. YoY, revenue decreased from $11.43B (Q2’25) to $10.87B (Q2’26), a decline of ~-4.9%, while net income fell from $255M to $60M (~-76.5%). QoQ, revenue rose slightly from $10.80B (Q1’26) to $10.87B (~+0.7%), but net income jumped from $14M to $60M (~+328.6%), indicating a rebound in earnings versus the prior quarter. Profitability remains volatile: net margin improved sequentially (0.13% in Q1’26 to 0.55% in Q2’26) but is still well below the year-ago quarter (2.23%). Operating income and operating margin tightened vs Q2’25 (operating margin ~3.26% down to ~1.33%). Cash flow quality weakened materially in the latest quarter: operating cash flow was -$294M and free cash flow -$324M, driven by working-capital drag (change in working capital of -$933M). Balance sheet resilience is supported by positive equity ($4.17B) and net cash (net debt of -$1.03B), though liquidity (cash + STI) declined QoQ. Total shareholder returns appear muted-to-negative: marketPerformance shows the stock down ~-55.2% over 1Y and ~-21.0% over 6M, implying no positive momentum boost. No dividends were paid (dividend yield 0) and buybacks were modest (~$14M in Q2’26). Analyst valuation context shows a wide target range with consensus below the stated current price."

Revenue Growth

Caution

Revenue was roughly flat sequentially (+0.7% QoQ: $10.80B to $10.87B) but down YoY (~-4.9%: $11.43B to $10.87B), indicating mild top-line deterioration.

Profitability

Neutral

Net margin improved QoQ (0.13% to 0.55%) and net income rebounded (+328.6% QoQ), but remains far below YoY levels (2.23% net margin in Q2’25 vs 0.55% in Q2’26). Operating margin fell vs year-ago (~3.26% to ~1.33%).

Cash Flow Quality

Neutral

Latest quarter cash generation was negative: operating cash flow -$294M and free cash flow -$324M, with a large working-capital drag (-$933M). This contrasts with strong OCF in Q1’26 (+$1.08B). No dividends paid.

Leverage & Balance Sheet

Positive

MOH maintains net cash (net debt -$1.03B) and solid equity (~$4.17B). Total assets decreased slightly QoQ (~$16.39B to $16.00B), suggesting resilience without reliance on leverage.

Shareholder Returns

Neutral

Market momentum is weak: price is down ~-55.2% over 1Y with 0% dividend yield. Buybacks were small (~$14M in Q2’26), so total shareholder return has likely been dominated by capital depreciation.

Analyst Sentiment & Valuation

Neutral

Provided targets imply limited upside versus the current market price context (consensus $198.23 vs price ~$148.97 is modest, with a wide range). Negative earnings momentum and FCF weakness in the latest quarter temper sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Molina posted Q2 2026 adjusted EPS of $1.51 on $10.2B premium with consolidated MCR of 92.2%, and management highlighted stability in medical cost trend (~5%). The key operating swing is Medicare duals: Q2 MCR 90.7% favorable and full-year Medicare MCR guide raised/improved to 92.2%, up 180 bps versus prior guidance, while duals now expected to earn $1.25 per share (offset by ~$1.00 MAPD loss). Medicaid remains the earnings stabilizer; 2026 EPS guidance rises $0.25 to at least $5.25 despite a still-heavy margin environment, with Medicaid MCR held at 92.9% and full-year pretax margin projected at 1.2%. The offsetting drag is Marketplace: full-year earnings cut to a $0.75 per share loss due to prior-year items and unfavorable current-year member acuity mix tied to risk adjustment mechanics (utilization not mapping to HCC). 2027 outlook stays constructive (premium ~$46.5B), but depends on continued Medicaid rate realization and controlled Marketplace footprint reduction.

AI IconGrowth Catalysts

  • Medicaid RFP reprocurement momentum: retained $2B managed Medicaid contract in Illinois and renewed Wisconsin regional contract to grow integrated duals
  • Medicare duals early margin outperformance: 2Q MCR 90.7% favorable; improved duals pricing implemented for 2026
  • 2026 Medicaid rate/trend balance stabilization: medical cost trend held stable at ~5% while rate updates consistent with ~4% guidance, supporting earlier-than-expected margin trajectory
  • Embedded earnings durability: new store embedded earnings remained at $9 per share with ~half anticipated to emerge in 2027

Business Development

  • Illinois: retained $2 billion managed Medicaid contract (reprocurement win)
  • Wisconsin: renewed regional contract supporting additional opportunity for integrated duals growth
  • California: decision to transition undocumented members into fee-for-service accounted for in 2027 premium outlook (premium headwind ~ $500 million)
  • Florida CMS contract: implementation in Q4 2026 referenced as a known drag impacting 2026 earnings (with reversal element discussed as embedded-earnings reversion/offset)

AI IconFinancial Highlights

  • 2Q 2026 adjusted EPS: $1.51; premium revenue: $10.2B
  • 2Q consolidated MCR: 92.2% (Medicaid 92.7%; Medicare 90.7%; Marketplace 88.9%)
  • Medical cost trend: stable and consistent with full-year guidance of ~5%
  • Pretax margin: 1.0% in the quarter; 1.3% year-to-date
  • Full-year 2026 guidance: premium ~ $42B unchanged; adjusted EPS raised by $0.25 to at least $5.25
  • Medicaid 2026 guidance: full-year MCR 92.9% unchanged; pretax margin expected 1.2% (up $0.25 vs prior), contributing ~ $5.75 per share
  • Medicare 2026 guidance: full-year MCR 92.2% (improves by 180 bps vs prior guidance) driven by lower medical cost trend in duals; duals expected to earn $1.25 per share; discontinued MAPD expected to lose ~$1.00 per share
  • Marketplace 2026 guidance: full-year MCR guidance cut to 90% and earnings guidance to loss of $0.75 per share (down $1.50 vs prior due to $1.00 prior-year items + worse current-year acuity mix)
  • Marketplace normalization: normalized MCR ex prior-year items was 87.3% (2Q); current-year member acuity mix remained unfavorable
  • 2026 earnings power framing: excluding Florida CMS contract losses and MAPD losses, 2026 earnings power is at least $7.75 per share

AI IconCapital Funding

  • Subsidiary dividend harvest in quarter: ~$110M
  • Parent company cash at quarter end: ~$290M
  • Operating cash flow first 6 months of 2026: ~$788M
  • Debt-to-cap: ~47% at quarter end; projected ~44% by year-end
  • Projected parent company cash at year-end: ~$600M
  • Days in claims payable: 44% (consistent with prior quarter)

AI IconStrategy & Ops

  • 2027 footprint reduction plan in Marketplace: reduce exposure by ~ $1B premium and further reduce volumes (California and broader Marketplace deemphasis)
  • Exchange economics continue to be managed via selective pricing/capital allocation rather than benefit/formulary design changes
  • Medicaid work requirement policy implementation expected to be gradual/protracted; management expects only minor acuity shift and continued capture via rates
  • Actuarial process/reserve confidence reaffirmed; guidance includes seasonality (Medicaid and Medicare split expected evenly in 2H vs 1H)

AI IconMarket Outlook

  • 2026 EPS guidance: at least $5.25 per share (up $0.25 from at least $5.00)
  • 2026 Medicaid: full-year MCR 92.9%, rates ~4% and medical cost trend ~5% unchanged
  • 2026 Medicare: full-year MCR 92.2% with first-half total Medicare MCR 90.3% improving to 93.8% in second half (seasonality)
  • 2026 Marketplace: full-year MCR guidance 90% and loss of $0.75 per share (includes ~$1.00 loss prior-year items and ~$0.25 gain from current-year book)
  • 2027 premium outlook: ~$46.5B (11% YoY growth vs $42B 2026 baseline) before capturing remaining items
  • 2027 planning assumptions: $1B premium reduction from Marketplace footprint reduction; ~$500M headwind from California undocumented-member transition to fee-for-service
  • 2027 rate update timing: ~55% of Molina premium scheduled to receive rate updates on January 1

AI IconRisks & Headwinds

  • Marketplace adverse selection/mix: 2026 pricing underestimated stickiness of high-cost members with utilization not translating into commensurate HCC—driving unfavorable risk adjustment and risk adjustment true-up/program integrity effects
  • Marketplace acuity dynamics: normalized ex prior-year items still affected by current-year member acuity mix
  • Work requirements implementation ambiguity: medical frailty definition, self-attestation acceptance, and legal challenges create uncertainty in early-year eligibility processes
  • CMS work requirements rule expected to cause gradual membership decline; management assumes minor acuity shift but relies on state actuaries capturing shifts in rates
  • Medicaid medical cost trend remains high but stable (~5%); potential reacceleration or off-cycle rate deviations remain a key sensitivity
  • Exchange risk pool migration could occur if high utilization members behave differently than expected; management implies market-wide stickiness and acuity shift are difficult to forecast

Q&A: Analyst Interest

  • Exchange EPS bridge and recurrence: Management attributed the revised Marketplace EPS path to a combination of prior-year items (risk adjustment true-ups and program integrity) and weaker current-year membership outlook. They emphasized ongoing need to price/capitalize selectively rather than redesign the product, with Wakely indicating the acuity shift in the overall market was less severe.
  • What drove Medicaid “slightly better” Q1 trend: Management said the trend environment was stable at ~5% and variance was mainly timing/lumpiness from the rate cycle (about 55% of revenue receives fresh rates on January 1). High-cost categories plateaued, and the prior-year 250 bps acuity shift did not recur.
  • What fixes Marketplace beyond rate changes: Management stated the issue was not formulary/benefit design or metallic tiering. The retained members were not individually higher acuity; rather, mix shift from retained high-cost, low-commensurate HCC members was underestimated. Fix depends on capital allocation/price levels and deemedphasizing states to reduce concentrated risk.

Sentiment: MIXED

Note: This summary was synthesized by AI from the MOH Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for MOH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (MOH)

© 2026 Stock Market Info — Molina Healthcare, Inc. (MOH) Financial Profile